Tyra Biosciences Inc (TYRA)

Jul 23, 2025

What analysts say about Tyra Biosciences Inc. stockHigh-octane gains - Autocar Professional

Jul 23, 2025

Jul 23, 2025

Tyra Biosciences (NASDAQ:TYRA) Trading Down 3% – Here’s Why - Defense World

Jul 23, 2025

Jul 23, 2025

Tyra Biosciences Inc. Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

What drives Tyra Biosciences Inc. stock priceExponential return rates - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Is Tyra Biosciences Inc. a good long term investmentRemarkable growth - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Why Tyra Biosciences Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser

Jul 22, 2025

Jul 21, 2025

Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series - Kilgore News Herald

Jul 21, 2025

Jul 21, 2025

June Brings on Some Huge Insider Buying - AOL.com

Jul 21, 2025

Jul 18, 2025

What analysts say about HOOK stockPhenomenal capital appreciation - jammulinksnews.com

Jul 18, 2025

Jul 18, 2025

Trading (TYRA) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 18, 2025

Jul 18, 2025

What drives Diana Shipping Inc. stock priceSuperior profit margins - Jammu Links News

Jul 18, 2025

Jul 18, 2025

What drives Third Harmonic Bio Inc. stock priceOutstanding risk-reward balance - jammulinksnews.com

Jul 18, 2025

Jul 16, 2025

Tyra Biosciences Rises On Precision Medicine Hopes And Analyst Support - Finimize

Jul 16, 2025

Jul 15, 2025

What makes Tyra Biosciences Inc. stock price move sharplySmart Return Focused Trading - Newser

Jul 15, 2025

Jul 15, 2025

How Tyra Biosciences Inc. stock performs during market volatilityInsider Strategy Insight - Newser

Jul 15, 2025

Jul 15, 2025

Tyra Biosciences Insider Lowered Holding By 58% During Last Year - simplywall.st

Jul 15, 2025

Jul 14, 2025

Advanced Urothelial Carcinoma Clinical Trials 2025: EMA, PDMA, - openPR.com

Jul 14, 2025

Jul 13, 2025

Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛

Jul 13, 2025

Jul 09, 2025

Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Eastern Progress

Jul 09, 2025

Jul 09, 2025

Tyra Biosciences' TYRA-300 Emerges as Dual-Threat Therapy, Poised to Drive Clinical and Market Momentum - AInvest

Jul 09, 2025

Jul 08, 2025

New TYRA-300 Preclinical Data Reveals Promising Results for Rare Bone Growth Disorder Treatment - Stock Titan

Jul 08, 2025

Jul 08, 2025

Where are the Opportunities in (TYRA) - news.stocktradersdaily.com

Jul 08, 2025

Jul 02, 2025

Tyra Biosciences’ (TYRA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jul 02, 2025

Jul 01, 2025

TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC - Targeted Oncology

Jul 01, 2025

Jun 30, 2025

Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - Longview News-Journal

Jun 30, 2025

Jun 30, 2025

Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Value Index - MarketScreener

Jun 30, 2025

Jun 30, 2025

Tyra Bioscience Launches Phase 2 Study for TYRA-300 - TipRanks

Jun 30, 2025